Split History
ETFs Holding ADMS »    ADMS Historical Stock Prices »
Video: What is a Stock Split?


If the video does not load after a few moments, Upgrade to the Latest Flash Player.
Adamas Pharmaceuticals is a pharmaceutical company focused on the development and commercialization of therapeutics targeting chronic disorders of the central nervous system. Co. is developing its wholly-owned product candidate, ADS-5102, for multiple indications including a complication associated with the treatment of Parkinson's disease known as levodopa-induced dyskinesia, and ADS-4101 compound for the treatment of epilepsy. Co.'s other product candidates include ADS-8704 for the treatment of moderate to severe dementia related to Alzheimer's disease. Co.'s portfolio also includes Namzaric™ and Namenda XR® extended release capsules for indications relating to Alzheimer's disease. According to our ADMS split history records, Adamas Pharmaceuticals has had 2 splits.
ADMS split history picture
Adamas Pharmaceuticals (ADMS) has 2 splits in our ADMS split history database. The first split for ADMS took place on February 16, 1999. This was a 3 for 2 split, meaning for each 2 shares of ADMS owned pre-split, the shareholder now owned 3 shares. For example, a 1000 share position pre-split, became a 1500 share position following the split. ADMS's second split took place on January 18, 2000. This was a 3 for 2 split, meaning for each 2 shares of ADMS owned pre-split, the shareholder now owned 3 shares. For example, a 1500 share position pre-split, became a 2250 share position following the split.

When a company such as Adamas Pharmaceuticals splits its shares, the market capitalization before and after the split takes place remains stable, meaning the shareholder now owns more shares but each are valued at a lower price per share. Often, however, a lower priced stock on a per-share basis can attract a wider range of buyers. If that increased demand causes the share price to appreciate, then the total market capitalization rises post-split. This does not always happen, however, often depending on the underlying fundamentals of the business. Looking at the ADMS split history from start to finish, an original position size of 1000 shares would have turned into 2250 today. Below, we examine the compound annual growth rate — CAGR for short — of an investment into Adamas Pharmaceuticals shares, starting with a $10,000 purchase of ADMS, presented on a split-history-adjusted basis factoring in the complete ADMS split history. ADMS split adjusted history picture

Growth of $10,000.00
Without Dividends Reinvested

Start date: 04/10/2014
End date: 04/25/2017
Start price/share: $14.01
End price/share: $16.36
Dividends collected/share: $0.00
Total return: 16.77%
Average Annual Total Return: 5.23%
Starting investment: $10,000.00
Ending investment: $11,678.56
Years: 3.04
Date Ratio
02/16/19993 for 2
01/18/20003 for 2
ADMS is categorized under the Healthcare sector; below are some other companies in the same sector that also have a history of stock splits:

ADPT Split History
ADXS Split History
AEZS Split History
AFAM Split History
AFFX Split History
AGN Split History
AHPI Split History
AIMT Split History
AIQ Split History
AIRM Split History

Rexahn Pharmaceuticals, Inc. (RNN)
Immune Pharmaceuticals Inc. (INMP)
DryShips Inc. (DRYS)
STRATA Skin Sciences, Inc. (SSKN)
Quantum Corp. (QTM)
German American Bancorp, Inc. (GABC)
Pacific Energy Development (PED)
The GEO Group, Inc. (GEO)
Copart, Inc. (CPRT)
HEICO Corporation (HEI)
More latest stock splits »
Latest mega mergers »
Latest stock buybacks »

ADMS Insider Buying

ADMS Split History | www.SplitHistory.com | Copyright © 2013 - 2017, All Rights Reserved

Nothing in www.SplitHistory.com is intended to be investment advice, nor does it represent the opinion of, counsel from, or recommendations by BNK Invest Inc. or any of its affiliates, subsidiaries or partners. Split history database is not guaranteed to be complete or free of errors. None of the information contained herein constitutes a recommendation that any particular security, portfolio, transaction, or investment strategy is suitable for any specific person. All viewers agree that under no circumstances will BNK Invest, Inc,. its subsidiaries, partners, officers, employees, affiliates, or agents be held liable for any loss or damage caused by your reliance on information obtained. By visiting, using or viewing this site, you agree to the following Full Disclaimer & Terms of Service. Video widget and market videos powered by Market News Video. Quote and option data delayed at least 15 minutes; stock quote data powered by Ticker Technologies, and Mergent.